Importantly, two studies also demonstrated the feasibility of utilizing PI3K blockade to generate CD19 CAR T cells with superior anti-tumor activity in xenograft models of chronic lymphocytic leukemia (CLL) and acute lymphocytic leukemia (ALL), using T cells derived from CLL patients (54, 57). This evidence concerns the gene CD19 and neoplasm.